0000000000455729
AUTHOR
M. Ross
showing 3 related works from this author
Present status and first results of the final focus beam line at the KEK Accelerator Test Facility
2011
ATF2 is a final-focus test beam line which aims to focus the low emittance beam from the ATF damping ring to a vertical size of about 37 nm and to demonstrate nanometer level beam stability. Several advanced beam diagnostics and feedback tools are used. In December 2008, construction and installation were completed and beam commissioning started, supported by an international team of Asian, European, and U.S. scientists. The present status and first results are described.
Comment on “Molybdenum sound velocity and shear modulus softening under shock compression”
2015
In this Comment we discuss recent results presented by Nguyen et al. on shock compressed molybdenum up to 438 GPa [Phys. Rev. B 89, 174109 (2014)]. The aim of Nguyen's article is to show that there is no phase transition near 210 GPa. We propose instead an interpretation of their data that this material shows the onset of partial melting along the Hugoniot at $240(20)\phantom{\rule{0.28em}{0ex}}\mathrm{GPa}$, which is evident from abrupt changes in the pressure dependence of the shear modulus. This interpretation may solve the significant controversy in the melting slopes derived from shock and static experiments.
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy
2021
BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included…